Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting

Los Angeles, CA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a NXC-201 abstract at the upcoming American Society of Hematology (ASH) 67^th Annual Meeting and Exposition to be held December 6-9, 2025, in Orlando, Florida.

Read more at globenewswire.com